摘要
目的探究血清C反应蛋白(CRP)、糖链抗原125(CA125)、癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)和神经元特异性烯醇化酶(NSE)检测在评估非小细胞肺癌外科手术治疗后预后的价值。方法收集非小细胞肺癌手术患者235例,采用罗氏e601免疫电化学发光分析仪检测血清CRP、CA125、CEA、CYFRA21-1和NSE水平,患者生存资料的随访从外科治疗开始计算直至死亡或观测时间结束,随访时间5年,最后进行统计学分析。结果不同病理分期非小细胞肺癌患者术后CRP、CA125、CEA、CYFRA21-1和NSE水平比较差异无统计学意义(P>0.05)。不同组织分类非小细胞肺癌患者术后CEA和CRP差异有统计学意义(P<0.05)。CRP≤15mg/L患者中位生存时间为79(14.85~88.2)个月,CRP>15mg/L患者中位生存时间为29.5(5.7~87.6)个月,差异有统计学意义(P=0.014)。CEA≤6ng/mL患者中位生存时间为68(12.25~68.5)个月,CEA>6ng/mL患者中位生存时间为31.2(5.9~67.4)个月,差异有统计学意义(P=0.009)。多因素分析表明,CRP>15 mg/L(OR=2.44,95%CI=1.83~6.89,P=0.003)、CEA>6ng/mL(OR=2.41,95%CI=2.05~9.97,P=0.004)及病理分期Ⅰa~Ⅱb与Ⅲ~Ⅳ(OR=4.89,95%CI=3.79~43.14,P=0.030)是预测非小细胞肺癌预后的独立危险因素。结论CRP>15 mg/L、CEA>6ng/mL及病理分期Ⅲ~Ⅳ期是预测非小细胞肺癌预后的独立危险因素。
Objective To investigate the value of serum CRP,CA125,CEA,CYFRA21-1and NSE in evaluating the prognosis of surgical treatment in non-small cell lung cancer（NSCLC）.Methods A total of 235 cases of NSCLC were collected and serum CRP,CA125,CEA,NSE and CYFRA21-1levels were detected by the Roche e601 immune electrochemiluminescence analyzer.The follow up of survival data was calculated from the surgical treatment beginning to death or the end of observation time,the follow time was five years.Then the statistically analysis was finally performed.Results There was no statistically significant difference in postoperative CRP,CA125,CEA,CYFRA21-1and NSE levels in the patients with different pathological stages of NSCLC（P〈0.05）.The postoperative CEA and CRP levels in the NSCLC patients had statistical difference among different histological classifications（P〈0.05）.Median survival time for the patients with CRP≤15mg/L was 79（14.85-88.2）months,which for patients with CRP15mg/L was 29.5（5.7-87.6）months,the difference was statistically significant（P=0.014）.Median survival time for the patients with CEA≤6ng/mL was 68（12.25-68.5）months,which for the patients with CEA6ng/mL was 31.2（5.9-67.4）months,the difference was statistically significant（P=0.009）.The multivariate analysis showed that CRP15mg/L（OR=2.44,95%CI=1.83-6.89,P=0.003）,CEA6ng/mL（OR=2.41,95%CI=2.05-9.97,P=0.004）and pathologic stageⅠa-Ⅱb vs.Ⅲ-Ⅳ（OR=4.89,95%CI=3.79-43.14,P=0.030）were the independent risk factors for predicting prognosis in NSCLC.ConclusionCRP15mg/L,CEA6ng/mL and pathologic stage Ⅲ-Ⅳ are the independent risk factors for predicting the prognosis in NSCLC.
出处
《检验医学与临床》
CAS
2017年第8期1107-1110,共4页
Laboratory Medicine and Clinic
关键词
非小细胞肺癌
血清
标志物
预后
non-small cell lung cancer
serum
markers
prognosis
